Literature DB >> 29751875

Chronic Hepatitis C and Direct Acting Antivirals.

Maria Westerhoff1, Joseph Ahn2.   

Abstract

The hepatitis C virus (HCV) is the most common blood-borne infection in the United States and is the most common cause of end-stage liver disease requiring liver transplant. Over the last 10 years, direct acting antiviral therapies have revolutionized HCV treatment, increasing the cure rates from less than 50% to more than 90% in those who reach access to care. This article is an overview for pathologists and clinicians covering the histologic findings of HCV as well as direct acting antiviral therapy.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnostic criteria; Directly acting antivirals; Hepatitis C; Histology; Liver biopsy; Transient elastography

Mesh:

Substances:

Year:  2018        PMID: 29751875     DOI: 10.1016/j.path.2018.02.002

Source DB:  PubMed          Journal:  Surg Pathol Clin        ISSN: 1875-9157


  1 in total

1.  Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages.

Authors:  Riichiro Suenaga; Machi Suka; Tomohiro Hirao; Isao Hidaka; Isao Sakaida; Haku Ishida
Journal:  PLoS One       Date:  2021-04-01       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.